Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia

J Wolf, LI Tang, PM Flynn, CH Pui… - Clinical Infectious …, 2017 - academic.oup.com
Background Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …
被引用次数：90 相关文章

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.

J Wolf, L Tang, PM Flynn, CH Pui, AH Gaur… - … Diseases: an Official …, 2017 - europepmc.org
Background Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia

J Wolf, L Tang, PM Flynn, CH Pui… - Clinical Infectious …, 2017 - academic.oup.com
Background Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.

J Wolf, L Tang, PM Flynn, CH Pui… - Clinical Infectious …, 2017 - search.ebscohost.com
Background. Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia

J Wolf, L Tang, PM Flynn, CH Pui, AH Gaur… - Clinical Infectious …, 2017 - JSTOR
Background. Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia

J Wolf, L Tang, PM Flynn, CH Pui… - … publication of the …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …

[引用][C] Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia

J Wolf, L Tang, PM Flynn, CH Pui, AH Gaur… - Clinical Infectious …, 2017 - cir.nii.ac.jp
Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic
Leukemia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia.

J Wolf, TL Tang Li, PM Flynn, PCH Pui ChingHon… - 2017 - cabidigitallibrary.org
Background: Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …

[引用][C] Levofloxacin Prophylaxis during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia

J Wolf, L Tang, PM Flynn, CH Pui… - Clinical Infectious …, 2017 - lomalinda.elsevierpure.com
Levofloxacin Prophylaxis during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia
— Faculty Research (Pure) - Loma Linda University Skip to main navigation Skip to search …
[HTML] nih.gov

[HTML][HTML] Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia

J Wolf, L Tang, PM Flynn, CH Pui, AH Gaur… - … Diseases: An Official …, 2017 - ncbi.nlm.nih.gov
Background Infection is the most important cause of treatment-related morbidity and
mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although …